Correlation Between Unicycive Therapeutics and OncoCyte Corp

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and OncoCyte Corp at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and OncoCyte Corp into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and OncoCyte Corp, you can compare the effects of market volatilities on Unicycive Therapeutics and OncoCyte Corp and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of OncoCyte Corp. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and OncoCyte Corp.

Diversification Opportunities for Unicycive Therapeutics and OncoCyte Corp

-0.75
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Unicycive and OncoCyte is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and OncoCyte Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OncoCyte Corp and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with OncoCyte Corp. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OncoCyte Corp has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and OncoCyte Corp go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and OncoCyte Corp

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.95 times more return on investment than OncoCyte Corp. However, Unicycive Therapeutics is 1.95 times more volatile than OncoCyte Corp. It trades about 0.36 of its potential returns per unit of risk. OncoCyte Corp is currently generating about -0.27 per unit of risk. If you would invest  48.00  in Unicycive Therapeutics on September 4, 2024 and sell it today you would earn a total of  26.00  from holding Unicycive Therapeutics or generate 54.17% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Unicycive Therapeutics  vs.  OncoCyte Corp

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
OncoCyte Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days OncoCyte Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Unicycive Therapeutics and OncoCyte Corp Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and OncoCyte Corp

The main advantage of trading using opposite Unicycive Therapeutics and OncoCyte Corp positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, OncoCyte Corp can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OncoCyte Corp will offset losses from the drop in OncoCyte Corp's long position.
The idea behind Unicycive Therapeutics and OncoCyte Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Commodity Directory
Find actively traded commodities issued by global exchanges